Cancerothorax360_AP-HP.centre
@cancerothorax
Followers
315
Following
519
Statuses
595
Actualité en #cancer poumon décryptée par l'équipe pluridisciplinaire de @AP-HP.centre @HopitalCochin @HopitalPompidou, Centre de Recherche des Cordeliers
Joined October 2020
RT @HopitalCochin: #praticienhospitalier | NOMINATIONS PH | 👏 Toutes nos félicitations aux 11 nouveaux praticiens hospitaliers nommés à l’@…
0
7
0
RT @StephenVLiu: Results from phase II LUMINOSITY trial of telisotuzumab vedotin (#MET ADC) in NSCLC now @JCO_ASCO. In cMET high, RR 34.6%,…
0
19
0
RT @StephenVLiu: OS from PACIFIC-R: real world outcomes with durvalumab (EAP) after chemoradiation for stage III NSCLC @ESMO_Open (n=1154).…
0
32
0
RT @StephenVLiu: Dr. Pan-Chyr Yang presents the Taiwan national lung cancer early detection program for heavy smokers & non-smokers w/ fami…
0
25
0
RT @BenjaminBesseMD: LIFETIME osimertinib after a treatment with curative intent? In pts with EGFRmut stage III NSCLC, chemo-radiotherapy c…
0
77
0
RT @StephenVLiu: TROPION-Lung01 press release: Trop2 ADC datopotamab deruxtecan vs docetaxel in previously treated NSCLC, previously met PF…
0
15
0
RT @StephenVLiu: Update from phase 3 IMscin001 trial @JTOonline. Pts with NSCLC randomized 2:1 to subcutaneous vs IV atezolizumab. Similar…
0
13
0
RT @DMSLung: Molecular and Pathologic Characterization of YAP1-Expressing Small Cell Lung Cancer Cell Lines Leads to Reclassification as SM…
0
4
0
RT @JTOonline: In this retrospective analysis, the authors found no significant differences in Stage I lung cancers incidentally or screeni…
0
2
0
RT @StephenVLiu: Among PDL1 high NSCLC, PFS and OS better with PDL1 ≥90% compared to 50-89%, report @JTOonline. Seen with 1L pembrolizumab…
0
27
0
RT @StephenVLiu: Prospective study of liquid biopsy in pts with #KRAS G12C NSCLC receiving sotorasib @JTOonline. Pts with detectable ctDNA…
0
8
0
RT @APHP: Les Troubles des Conduites Alimentaires touchent plus de 100 000 jeunes en France. Découvrez la @MaisondeSolenn, une maison des…
0
10
0
RT @StephenVLiu: Editorial on ALINA (adjuvant alectinib for resected #ALK NSCLC) from Drs. @APassaroMD @peters_solange in @NEJM. Acknowledg…
0
24
0
RT @StephenVLiu: Phase III ALINA trial of adjuvant alectinib for resected stage Ib-IIIA (AJCC v7) #ALK NSCLC now @NEJM. Compared 2y of alec…
0
34
0
RT @InstParisCarpem: [Rappel] 28 juin 2024 - 4ème Journée de l’innovation en cancérologie thoracique médico-chirurgicale, organisée par les…
0
7
0
RT @MarieWislez: AbbVie Inc. AbbVie annonce les premiers résultats positifs de l'étude de phase 2 Luminosity évaluant le telisotuzumab-vedo…
0
4
0
RT @ElizSMcKenna: Now online in @CD_AACR: Activating Point Mutations in the MET Kinase Domain Represent a Unique Molecular Subset of #LungC…
0
16
0
RT @Dr_R_Kurzrock: Hear ye hear ye! FDA grants accelerated approval to fam-trastuzumab deruxtecan-nxki for unresectable or metastatic HER2…
0
23
0
RT @PTarantinoMD: T-DXd is approved for the treatment of patients with ANY treatment-refractory HER2+ (IHC 3+) tumor, making of it the firs…
0
114
0